ArticleACS omega2025
Development of a Prostate-Specific Antigen Targeted Dual Drug Conjugate for Prostate Cancer Therapy.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Comprehensive Review on Engineering Release at the Molecular Level: Role of Functional Groups in Polysaccharide-Based Drug Delivery.Materials (Basel, Switzerland) · 2026Review
- A PSMA-targeted dextran-based conjugate eradicates PSMA-overexpressing prostate tumors while abolishing cabazitaxel toxicity.Theranostics · 2026Article
- Drug Discovery Strategies for Kallikrein-Related Peptidases.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PC) is the most frequently diagnosed cancer and the second leading cause of cancer deaths in American men. While localized cases can be cured through surgery or local radiation, metastatic PC lacks curative therapy. The challenges to the success of treating advanced PC include the adverse effects of current treatment strategies, the continuous generation of cancer cells by cancer stem cells, and tumor heterogeneity. To overcome these challenges, researchers have explored the prodrug approach for targeted, combination drug delivery or release of cytotoxic agents specifically to sites of metastatic PC to improve therapeutic efficacy while decreasing systemic toxicity. The objective of this study is to develop a dual drug conjugate with a prostate-specific antigen (PSA) peptide recognition sequence for PC-specific combination SN-38 and cabazitaxel delivery in the treatment of advanced PC. To achieve this, His-Ser-Ser-Lys-Leu-Glu terminated with the dibenzocyclooctyne (DBCO) functional group conjugated to SN-38 via a leucine spacer was synthesized. Similarly, His-Ser-Ser-Lys-Leu-Glu terminated with azido poly(ethylene glycol) conjugated to cabazitaxel via a leucine spacer was synthesized. The conjugates were linked together via click chemistry to synthesize a dual drug conjugate. In vitro exposure to exogenous PSA was found to trigger the release of cytotoxic drugs. The dual drug conjugate exhibited time- and concentration-dependent cytotoxicity in PC-3 and LNCaP PC cells. The observed cytotoxicity was also dependent on PSA expression in the cellular models tested. This study demonstrates the potential of peptide-drug conjugates for the delivery of combination chemotherapeutics for selective cytotoxicity to PC cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.